Top 10 Stocks Under $5 That Could Triple

8. Sagimet Biosciences Inc. (NASDAQ:SGMT)

Sagimet Biosciences Inc. (NASDAQ:SGMT) earns a place on our list of the top 10 stocks under $5 that could triple.

As of March 19, 2026, 91% of analysts remain bullish on Sagimet Biosciences Inc. (NASDAQ:SGMT). The stock boasts a consensus price target of $27.50, indicating an upside of 437.27%.

On March 11, 2026, in its fourth-quarter and full-year 2025 financial results update, Sagimet Biosciences Inc. (NASDAQ:SGMT) emphasized ongoing pipeline momentum, which strengthened investor confidence. In the second half of 2026, the company plans to commence a Phase 2 trial in F4 MASH patients. This development comes after the company successfully completed a Phase 1 pharmacokinetic trial, assessing denifanstat in combination with resmetirom, with no significant adverse effects.

Its ongoing first-in-human Phase 1 trial for TVB-3567, which targets acne, is another example of Sagimet Biosciences Inc.’s (NASDAQ:SGMT) progress. Additionally, Ascletis, a partner, published positive Phase 3 acne data and obtained NDA acceptance in China.

In terms of finances, Sagimet Biosciences Inc. (NASDAQ:SGMT) concluded 2025 with $113.1 million in cash, $39.1 million in R&D costs, and a $51.0 million net loss as opposed to a $45.6 million loss in 2024.

Importantly, HC Wainwright reaffirmed its “Buy” rating that same day, demonstrating confidence in the stock.

Sagimet Biosciences Inc. (NASDAQ:SGMT) is a clinical-stage biopharmaceutical company developing FASN inhibitors, such as denifanstat, to address metabolic and dermatological disorders, particularly for MASH and acne treatments.